Timing note: Pfizer is scheduled to release its second-quarter results this morning, Tuesday, August 4, 2026, rather than tomorrow. The analyst call begins at 10:00 a.m. ET. (pfizer.com)
| Metric | Q2 2026 expectation | Q2 2025 actual |
|---|---|---|
| Revenue | ~$14.4 billion | $14.65 billion |
| Adjusted EPS | ~$0.68 | $0.78 |
Consensus therefore implies modest revenue contraction and a more pronounced year-over-year decline in adjusted EPS. The EPS estimate is approximately $0.68, while available consensus data place revenue near $14.4 billion. (tipranks.com)
Pfizer enters the report after a solid first quarter: revenue was $14.45 billion and adjusted EPS was $0.75. The product mix was encouraging—Padcev, Lorbrena, Nurtec and Eliquis grew—but Comirnaty and Paxlovid remained significant offsets. (sec.gov)
The central question is not whether Pfizer can beat a relatively modest quarterly earnings bar. It is whether the company can demonstrate that growth products, pipeline progress and cost savings are building a credible bridge across its upcoming patent-expiration cycle.
Pfizer has reaffirmed 2026 guidance twice, most recently following the June CFO-transition announcement:
The original outlook assumed roughly $5 billion of COVID-product revenue, approximately $1.5 billion below 2025, plus another approximately $1.5 billion headwind from loss of exclusivity. (pfizer.com)
Investor interpretation:
Pfizer earned $0.75 in Q1. If Q2 lands near $0.68, first-half adjusted EPS would be about $1.43, leaving roughly $1.37 to $1.57 needed in the second half to meet guidance. That appears achievable given the seasonality of Comirnaty, but it leaves execution dependent on the autumn vaccine season and continued expense control.
Pfizer’s Q1 revenue rose 5% as reported, but the underlying picture was more important: the company reported 7% operational growth excluding Comirnaty and Paxlovid, while its recently launched and acquired products grew 22% operationally.
The key Q2 product trends are:
Investors should focus less on individual penny-level product beats and more on whether these assets collectively maintain double-digit growth. The group needs to offset declines in COVID products, Ibrance and other medicines facing competition.
Padcev’s opportunity expanded materially in July when the FDA approved Padcev plus Keytruda as perioperative treatment for muscle-invasive bladder cancer regardless of cisplatin eligibility. The approval was supported by EV-304, where the regimen reduced the risk of recurrence, progression or death by 47% compared with standard chemotherapy. (pfizer.com)
Because the broader approval came after the second quarter ended, it will not materially affect reported Q2 sales. Management commentary on launch preparation, physician adoption and the longer-term size of the earlier-stage market could nevertheless influence expectations for 2027 and beyond.
Comirnaty and Paxlovid declined sharply in Q1:
Pfizer has emphasized that Comirnaty revenue is heavily weighted toward the second half, while low COVID infection levels may continue to pressure Paxlovid. Q2 COVID sales should therefore be judged against full-year assumptions rather than in isolation.
The important questions are:
The European authorization of the updated XFG-adapted vaccine is operationally positive, but investors still need visibility into autumn demand and U.S. vaccine policy. (pfizer.com)
Q1 adjusted cost of sales rose sharply and adjusted gross margin was approximately 76%. Pfizer attributed part of the year-over-year pressure to the non-recurrence of a favorable royalty adjustment, product mix and foreign exchange.
At the same time:
The constructive outcome would be continued SI&A discipline and manufacturing savings funding higher-value pipeline investment without compromising adjusted operating margins.
Watch for:
The pipeline discussion could matter as much as the financial results.
June data supported advancing berobenatide, Pfizer’s ultra-long-acting GLP-1 receptor agonist acquired with Metsera. Weekly dosing produced almost 16% non-placebo-adjusted weight loss at 32 weeks without an observed plateau, while monthly maintenance dosing showed favorable tolerability. Pfizer plans ten Phase 3 berobenatide studies as part of more than 20 obesity trials. (pfizer.com)
Investors should seek answers on:
Berobenatide does not solve Pfizer’s near-term growth problem, but success could materially improve the company’s post-2028 outlook.
The expanded Padcev approval strengthens the commercial side of the Seagen acquisition. However, sigvotatug vedotin failed to demonstrate a statistically significant overall-survival improvement over docetaxel in the overall population of the Phase 3 SigVie-002 lung-cancer trial. Pfizer observed a more encouraging trend in second-line patients and is continuing earlier-line combination studies. (pfizer.com)
Management needs to explain:
Other recent positives include successful Phase 3 vitiligo studies for Litfulo, expanded Ibrance and Hympavzi approvals, and FDA priority review for Talzenna plus Xtandi. Litfulo met its U.S. co-primary endpoints in two Phase 3 studies without new safety signals. (pfizer.com)
Dave Denton will leave Pfizer on August 15, with Cecile Guegan becoming interim CFO on August 16. Pfizer reaffirmed guidance when announcing the transition, reducing the likelihood that the departure reflected an undisclosed near-term financial issue. Nevertheless, investors will want continuity on cost discipline, leverage and capital deployment. (pfizer.com)
Relevant topics include:
The board maintained the quarterly dividend at $0.43 per share. At the August 3 closing price of roughly $25.04, that represents an indicated annual yield of approximately 6.9%. (pfizer.com)
PFE closed August 3 at approximately $25.04. That is about:
The valuation already discounts weak near-term growth and considerable pipeline uncertainty. But a low multiple alone may not produce upside: investors need evidence that the dividend is supported, the patent-expiration period is manageable and the acquired pipeline will eventually generate meaningful revenue.
The shares could respond positively if Pfizer delivers:
A modest beat combined with unchanged guidance is likely to produce a muted reaction. Investors may view the quarter as adequate but continue waiting for stronger evidence of post-2028 growth.
The most negative combination would be:
The Q2 earnings bar is manageable, but the strategic bar is higher. Pfizer needs to show that its underlying commercial portfolio is growing fast enough to absorb COVID normalization and patent losses, while cost savings fund—rather than merely mask—heavy pipeline investment.
The most important indicators will be:
A clean quarter and guidance raise could reinforce the value-and-income thesis. A simple consensus beat without improved long-term visibility is less likely to change the market’s cautious view.